<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675255</url>
  </required_header>
  <id_info>
    <org_study_id>202008043</org_study_id>
    <nct_id>NCT04675255</nct_id>
  </id_info>
  <brief_title>Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism</brief_title>
  <acronym>ADIPOSITY</acronym>
  <official_title>WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A substudy of TMC114FD2HTX4004 that will perform glucose tolerance testing, adipose testing&#xD;
      and MRI scan at baseline, 12 and 24 weeks post switch of ART medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Synopsis Full study title: Assessing the impact of integrase strand transfer inhibitors&#xD;
      (INSTI) to protease inhibitor (PI) switch on insulin sensitivity and fat metabolism&#xD;
      (ADIPOSITY): a sub-study of DEFINE&#xD;
&#xD;
      Endpoints and objectives:&#xD;
&#xD;
      The following endpoints will be determined 12 and 24 weeks after switch from an INSTI-based&#xD;
      antiretroviral therapy (ART) regimen to a PI-based regimen:&#xD;
&#xD;
      Primary endpoint: Change in insulin sensitivity (SI) at 12 weeks assessed by using a 3-hour&#xD;
      frequently sampled oral glucose tolerance testing (fsOGTT).&#xD;
&#xD;
      Secondary endpoints: 1) Change in insulin sensitivity (SI) at 24 weeks assessed by using a&#xD;
      3-hour frequently sampled oral glucose tolerance testing (fsOGTT); 2) Change in insulin&#xD;
      secretion during the fsOGTT assessed by using C-peptide deconvolution; 3) Change in&#xD;
      intrahepatic triglyceride (IHTG) content measured by magnetic resonance imaging (MRI); 4)&#xD;
      Change in adipocyte size by the osmium tetroxide fixation technique; and 5) Change in&#xD;
      expression of genes associated with adipose tissue development, lipogenesis, inflammation and&#xD;
      endocrine function by RNA sequencing.&#xD;
&#xD;
      Hypothesis: Insulin sensitivity will improve following switch from INSTIs to PIs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity measured by homeostatic model assessment for insulin resistance {HOMA_IR}</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in insulin sensitivity (SI) at 12 weeks assessed by using a 3-hour frequently sampled oral glucose tolerance testing (fsOGTT).to calculate HOMA_IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic triglyceride (IHTG) content measure by magnetic resonance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in intrahepatic triglyceride (IHTG) content measured by magnetic resonance imaging (MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic triglyceride (IHTG) content measure by magnetic resonance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in intrahepatic triglyceride (IHTG) content measured by magnetic resonance imaging (MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipocyte size measured by osmium tetroxide fixation technique</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in adipocyte size by the osmium tetroxide fixation technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipocyte size measured by osmium tetroxide fixation technique</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in adipocyte size by the osmium tetroxide fixation technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipocyte gene expression correlated with adipose tissue development</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in expression of adipose tissue genes correlated with adipose tissue development, lipogenesis, inflammation and endocrine function measured by RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipocyte gene expression correlated with adipose tissue development</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in expression of adipose tissue genes correlated with adipose tissue development, lipogenesis, inflammation and endocrine function measured by RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity measured by homeostatic model assessment for insulin resistance {HOMA_IR}</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in insulin sensitivity (SI) at 12 weeks assessed by using a 3-hour frequently sampled oral glucose tolerance testing (fsOGTT).to calculate HOMA_IR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HIV I Infection</condition>
  <condition>Adiposity</condition>
  <arm_group>
    <arm_group_label>Immediate switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate switch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed switch</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Frequently sampled glucose tolerance testing</intervention_name>
    <description>Frequently sampled glucose tolerance testing</description>
    <arm_group_label>Delayed switch</arm_group_label>
    <arm_group_label>Immediate switch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>abdominal subcutaneous adipose tissue biopsy</intervention_name>
    <description>abdominal subcutaneous adipose tissue biopsy</description>
    <arm_group_label>Delayed switch</arm_group_label>
    <arm_group_label>Immediate switch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI scan to assess intrahepatic triglyceride content</intervention_name>
    <description>MRI scan to assess intrahepatic triglyceride content</description>
    <arm_group_label>Delayed switch</arm_group_label>
    <arm_group_label>Immediate switch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Must be enrolled in the DEFINE study TMC114FD2HTX4004&#xD;
&#xD;
               -  Must sign an ICF indicating that they understand the purpose of, and procedures&#xD;
                  required for, the study and are willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Contraindication to magnetic resonance imaging as determined by institutional&#xD;
             policy.&#xD;
&#xD;
               -  Current diagnosis of diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane O'Halloran, MB BA PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine in St. Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane O'Halloran, MB BA PhD</last_name>
    <phone>314 454 0058</phone>
    <email>janeaohalloran@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Klebert, PhD RN</last_name>
    <phone>3147471098</phone>
    <email>mklebert@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Klebert, RN PhD</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jane O'Hallorhan, MB BA PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Presti, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jane O'Halloran</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Internal Medicine - Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

